Analyzing Nexvet Biopharma (NVET) & Its Rivals
Nexvet Biopharma (NASDAQ: NVET) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Nexvet Biopharma to similar businesses based on the strength of its earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and risk.
Institutional & Insider Ownership
48.4% of Nexvet Biopharma shares are held by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 37.0% of Nexvet Biopharma shares are held by insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and price targets for Nexvet Biopharma and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Nexvet Biopharma Competitors||893||3287||11783||235||2.70|
Nexvet Biopharma currently has a consensus price target of $6.72, suggesting a potential upside of 0.00%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.32%. Given Nexvet Biopharma’s peers stronger consensus rating and higher possible upside, analysts clearly believe Nexvet Biopharma has less favorable growth aspects than its peers.
This table compares Nexvet Biopharma and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Nexvet Biopharma Competitors||-5,106.81%||-173.05%||-36.62%|
Valuation and Earnings
This table compares Nexvet Biopharma and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Nexvet Biopharma Competitors||$284.49 million||$34.10 million||66.29|
Nexvet Biopharma’s peers have higher revenue and earnings than Nexvet Biopharma. Nexvet Biopharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Nexvet Biopharma peers beat Nexvet Biopharma on 8 of the 11 factors compared.
About Nexvet Biopharma
Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company’s advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).
Receive News & Stock Ratings for Nexvet Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexvet Biopharma and related stocks with our FREE daily email newsletter.